Benztropine, with the chemical formula 3alpha-diphenylmethoxytropane, is a tropane-based dopamine inhibitor used for the symptomatic treatment of Parkinson's disease. It is a combination molecule between a tropane ring, similar to cocaine, and a diphenyl ether from the dialkylpiperazines determined to be a dopamine uptake inhibitor since 1970. The generation of structure-activity relationships proved that benztropine derivatives with the presence of a chlorine substituent in the para position in one of the phenyl rings produces an increased potency for dopamine uptake inhibition as well as a decreased inhibition of serotonin and norepinephrine. Benztropine was developed by USL Pharma and officially approved by the FDA on 1996.
用于治疗帕金森病。也用于药物引起的锥体外系疾患,口服1小时起效,肌肉或静脉注射数分钟内起效,作用持续24小时。具有抗胆碱及抗组胺作用,并有轻度局部麻醉作用。
Shanghai Chest Hospital, Shanghai, Shanghai, China
Research Cinic for Functional Disorders, Aarhus, Denmark
Dihydroergot mesylate, Nanjing, Jiangsu, China
University of Texas Southwestern Medical Center, Dallas, Texas, United States
University of Texas Southwestern Medical Center, Dallas, Texas, United States
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Beijing Cancer Hospital, Beijing, Beijing, China
Peking University Third Hospital, Beijing, Beijing, China
NEXT Oncology, 2829 Babcock Road Suite 300, San Antonio, Texas, United States
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
Tzu Chi General Hospital, Taipei Branch, New Taipei City, Taiwan
Jieer Ying, Hangzhou, Zhejiang, China
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.